<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, May 4, 2020 (HealthDay News) — Recommendations are presented for the management of eosinophilic esophagitis (EoE) in clinical practice guidelines published in the May issue of Gastroenterology<\/i>.<\/p>\n
Ikuo Hirano, M.D., from Northwestern University Feinberg School of Medicine in Chicago, and colleagues developed recommendations for clinical management of EoE for pediatric and adult allergists and gastroenterologists; the recommendations are applicable to short-term treatment of EoE.<\/p>\n
According to the recommendations, proton pump inhibition therapy is suggested over no treatment for patients with symptomatic esophageal eosinophilia. In patients with EoE, topical glucocorticosteroids are recommended over no treatment; topical glucocorticosteroids are suggested rather than oral glucocorticosteroids. An elemental diet or an empiric six-food elimination diet is suggested over no treatment for patients with EoE; these treatment options will likely be declined by patients who put a higher value on avoiding the challenges associated with adherence to an elemental diet or a diet involving elimination of multiple common food staples. An allergy testing-based elimination diet is suggested over no treatment for patients with EoE. For patients in remission after short-term topical glucocorticosteroid use, continuation of topical glucocorticosteroids is suggested over discontinuation of treatment. Anti-interleukin-5 (IL-5), anti-IL-13, or anti IL-4 receptor-\u03b1 therapy is recommended only in the context of a clinical trial. The researchers note that new targeted biologic therapies for EoE are currently being evaluated and more research is necessary before a recommendation can be provided on their use.<\/p>\n
“As the field moves forward, a deeper understanding of the natural history of EoE in both children and adults is needed to inform clinical decisions regarding the optimal use of disease monitoring and long-term, maintenance therapy,” Hirano said in a statement.<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies.<\/p>\n
Guidelines (subscription or payment may be required)<\/a> <\/i><\/p>\n
\nTechnical Review (subscription or payment may be required)<\/a><\/p>\n